211 related articles for article (PubMed ID: 35494533)
21. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
Michot JM; Lazarovici J; Tieu A; Champiat S; Voisin AL; Ebbo M; Godeau B; Michel M; Ribrag V; Lambotte O
Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647
[TBL] [Abstract][Full Text] [Related]
22. Immune checkpoint inhibitor-related hypophysitis.
Mizukoshi T; Fukuoka H; Takahashi Y
Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101668. PubMed ID: 35562229
[TBL] [Abstract][Full Text] [Related]
23. Development of autoimmune diabetes with severe diabetic ketoacidosis and immune-related thyroiditis secondary to durvalumab: a case report.
Lopes AR; Russo A; Li AY; McCusker MG; Kroopnick JM; Scilla K; Mehra R; Rolfo C
Transl Lung Cancer Res; 2020 Oct; 9(5):2149-2156. PubMed ID: 33209634
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy-Induced Anterior Hypophysitis.
Pachika PS; Khanam R; Faisal S; Ahmad T; Chandrasekhara Pillai A
Cureus; 2021 Jul; 13(7):e16538. PubMed ID: 34430146
[TBL] [Abstract][Full Text] [Related]
25. Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review.
Stelmachowska-Banaś M; Czajka-Oraniec I
Endocr Connect; 2020 Oct; 9(10):R207-R228. PubMed ID: 33064663
[TBL] [Abstract][Full Text] [Related]
26. Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events.
Poto R; Troiani T; Criscuolo G; Marone G; Ciardiello F; Tocchetti CG; Varricchi G
Front Immunol; 2022; 13():804597. PubMed ID: 35432346
[TBL] [Abstract][Full Text] [Related]
27. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
28. Diabetic Ketoacidosis: An Adverse Reaction to Immunotherapy.
Keerty D; Das M; Hallanger-Johnson J; Haynes E
Cureus; 2020 Sep; 12(9):e10632. PubMed ID: 33123445
[TBL] [Abstract][Full Text] [Related]
29. Case Report: Keratoacanthoma and type I diabetes secondary to treatment with PM8001, a bifunctional fusion protein targeting TGF-β and PD-L1.
Qi R; Xu H; Fu X; Yu Y; Lv D; Li Y; He S
Front Oncol; 2023; 13():1046266. PubMed ID: 37593095
[TBL] [Abstract][Full Text] [Related]
30. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
[TBL] [Abstract][Full Text] [Related]
31. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
32. Endocrine sequelae of immune checkpoint inhibitors.
Ntali G; Kassi E; Alevizaki M
Hormones (Athens); 2017 Oct; 16(4):341-350. PubMed ID: 29518754
[TBL] [Abstract][Full Text] [Related]
33. Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism.
Patel S; Chin V; Greenfield JR
Endocrinol Diabetes Metab Case Rep; 2019 Dec; 2019():. PubMed ID: 31829972
[TBL] [Abstract][Full Text] [Related]
34. Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype.
Marchand L; Thivolet A; Dalle S; Chikh K; Reffet S; Vouillarmet J; Fabien N; Cugnet-Anceau C; Thivolet C
Acta Diabetol; 2019 Apr; 56(4):441-448. PubMed ID: 30284618
[TBL] [Abstract][Full Text] [Related]
35. Clinical Characteristics, Management, and Potential Biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors.
Iwama S; Kobayashi T; Arima H
Endocrinol Metab (Seoul); 2021 Apr; 36(2):312-321. PubMed ID: 33934588
[TBL] [Abstract][Full Text] [Related]
36. Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies.
Ferrari SM; Fallahi P; Elia G; Ragusa F; Ruffilli I; Patrizio A; Galdiero MR; Baldini E; Ulisse S; Marone G; Antonelli A
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137683
[TBL] [Abstract][Full Text] [Related]
37. PD-1 inhibitor therapy causes multisystem immune adverse reactions: a case report and literature review.
Yin N; Liu X; Ye X; Song W; Lu J; Chen X
Front Oncol; 2022; 12():961266. PubMed ID: 36119464
[TBL] [Abstract][Full Text] [Related]
38. Two Cases of Atezolizumab-Induced Hypophysitis.
Kanie K; Iguchi G; Bando H; Fujita Y; Odake Y; Yoshida K; Matsumoto R; Fukuoka H; Ogawa W; Takahashi Y
J Endocr Soc; 2018 Jan; 2(1):91-95. PubMed ID: 29362727
[TBL] [Abstract][Full Text] [Related]
39. Anti‑PD‑1 immune checkpoint inhibitor inducing endocrine toxicity in a patient with advanced lung cancer: A case report and literature review.
Bao S; Jiang X
Exp Ther Med; 2022 Nov; 24(5):681. PubMed ID: 36185768
[TBL] [Abstract][Full Text] [Related]
40. Efficacies of programmed cell death 1 ligand 1 blockade in non-small cell lung cancer patients with acquired resistance to prior programmed cell death 1 inhibitor and development of diabetic ketoacidosis caused by two different etiologies: a retrospective case series.
Ishi A; Tanaka I; Iwama S; Sakakibara T; Mastui T; Kobayashi T; Hase T; Morise M; Sato M; Arima H; Hashimoto N
Endocr J; 2021 May; 68(5):613-620. PubMed ID: 33790087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]